Repligen Stock Performance
RGEN Stock | USD 167.86 3.42 2.00% |
The company holds a Beta of 2.24, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Repligen will likely underperform. Repligen has an expected return of -0.2%. Please make sure to check Repligen treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Repligen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Repligen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in May 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (2.36) | Five Day Return 6.1 | Year To Date Return (6.72) | Ten Year Return 967.94 | All Time Return 1.4 K |
1 | Strength Seen in Repligen Can Its 4.3 percent Jump Turn into More Strength | 01/29/2024 |
2 | Repligen Q4 Earnings Snapshot | 02/21/2024 |
3 | Acquisition by James Bylund of 404 shares of Repligen subject to Rule 16b-3 | 02/29/2024 |
4 | Disposition of 820 shares by James Bylund of Repligen at 191.79 subject to Rule 16b-3 | 03/01/2024 |
5 | Disposition of tradable shares by James Bylund of Repligen at 195.52 subject to Rule 16b-3 | 03/05/2024 |
6 | Disposition of 386 shares by Christine Gebski of Repligen at 195.72 subject to Rule 16b-3 | 03/07/2024 |
7 | Acquisition by Ralf Kuriyel of 1271 shares of Repligen at 86.1 subject to Rule 16b-3 | 03/11/2024 |
8 | Repligen Corp CEO Anthony Hunt Sells 16,707 Shares | 03/12/2024 |
9 | Repligen adds industry veteran Maggie Pax to board | 03/19/2024 |
10 | Global Upstream Bioprocessing Market Projected to Reach 25 Billion by 2030 - Analysis by Product Type, Workflow, Usage Type, Mode, and Region | 03/20/2024 |
11 | B. Riley Wealth Advisors Inc. Lowers Stock Position in Repligen Co. - Defense World | 03/25/2024 |
12 | Disposition of 444 shares by James Bylund of Repligen at 182.95 subject to Rule 16b-3 | 04/02/2024 |
13 | Cell Expansion Market is Expected to Reach 26.7 billion MarketsandMarkets | 04/11/2024 |
14 | Repligen to Report First Quarter 2024 Financial Results | 04/17/2024 |
15 | Should be Confident in Repligen Corporation s Long-Term Growth Potential | 04/23/2024 |
Begin Period Cash Flow | 523.5 M |
Repligen |
Repligen Relative Risk vs. Return Landscape
If you would invest 19,340 in Repligen on January 26, 2024 and sell it today you would lose (2,554) from holding Repligen or give up 13.21% of portfolio value over 90 days. Repligen is currently does not generate positive expected returns and assumes 2.264% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Repligen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Repligen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Repligen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Repligen, and traders can use it to determine the average amount a Repligen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0897
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | RGEN |
Estimated Market Risk
2.26 actual daily | 20 80% of assets are more volatile |
Expected Return
-0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Repligen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Repligen by adding Repligen to a well-diversified portfolio.
Repligen Fundamentals Growth
Repligen Stock prices reflect investors' perceptions of the future prospects and financial health of Repligen, and Repligen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Repligen Stock performance.
Return On Equity | 0.0214 | ||||
Return On Asset | 0.0131 | ||||
Profit Margin | 0.07 % | ||||
Operating Margin | 0.05 % | ||||
Current Valuation | 8.74 B | ||||
Shares Outstanding | 55.84 M | ||||
Price To Earning | 154.58 X | ||||
Price To Book | 4.86 X | ||||
Price To Sales | 14.99 X | ||||
Revenue | 638.76 M | ||||
Gross Profit | 455.71 M | ||||
EBITDA | 131.39 M | ||||
Net Income | 41.58 M | ||||
Cash And Equivalents | 596.51 M | ||||
Cash Per Share | 10.75 X | ||||
Total Debt | 711.8 M | ||||
Debt To Equity | 0.23 % | ||||
Current Ratio | 2.30 X | ||||
Book Value Per Share | 35.35 X | ||||
Cash Flow From Operations | 113.92 M | ||||
Earnings Per Share | 0.74 X | ||||
Market Capitalization | 9.56 B | ||||
Total Asset | 2.82 B | ||||
Retained Earnings | 438.85 M | ||||
Working Capital | 952.88 M | ||||
Current Asset | 103.25 M | ||||
Current Liabilities | 18.78 M | ||||
About Repligen Performance
To evaluate Repligen Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Repligen generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Repligen Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Repligen market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Repligen's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 208.30 | 132.74 | |
Return On Tangible Assets | 0.03 | 0.03 | |
Return On Capital Employed | 0.02 | 0.02 | |
Return On Assets | 0.01 | 0.02 | |
Return On Equity | 0.02 | 0.02 |
Things to note about Repligen performance evaluation
Checking the ongoing alerts about Repligen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Repligen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Repligen generated a negative expected return over the last 90 days | |
Repligen is unlikely to experience financial distress in the next 2 years | |
Repligen has a strong financial position based on the latest SEC filings | |
Over 93.0% of the company shares are owned by institutional investors | |
Latest headline from finance.yahoo.com: Should be Confident in Repligen Corporation s Long-Term Growth Potential |
- Analyzing Repligen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Repligen's stock is overvalued or undervalued compared to its peers.
- Examining Repligen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Repligen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Repligen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Repligen's stock. These opinions can provide insight into Repligen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.Note that the Repligen information on this page should be used as a complementary analysis to other Repligen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Repligen Stock analysis
When running Repligen's price analysis, check to measure Repligen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repligen is operating at the current time. Most of Repligen's value examination focuses on studying past and present price action to predict the probability of Repligen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repligen's price. Additionally, you may evaluate how the addition of Repligen to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Repligen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Earnings Share 0.74 | Revenue Per Share 11.464 | Quarterly Revenue Growth (0.17) | Return On Assets 0.0131 |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.